Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients

References

• Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet. 2021;397(10281):1–8. doi:10.1016/S0140-6736(20)32549-6.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi:10.1016/S0140-6736(21)00184-7.
   PubMed Web of Science ®Google Scholar
• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi:10.1111/jdv.13854.
   PubMed Web of Science ®Google Scholar
• Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173–1179. doi:10.1001/jamadermatol.2013.5015.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. Jama. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. 2017;77(4):657–666.e8. doi:10.1016/j.jaad.2017.04.1133.
   PubMed Web of Science ®Google Scholar
• Langan SM, Seminara NM, Shin DB, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3 Pt 1):556–562. doi:10.1038/jid.2011.365.
   PubMed Web of Science ®Google Scholar
• Liu L, Cai XC, Sun XY, et al. Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence. J Eur Acad Dermatol Venereol. 2022;36(11):1969–1979. doi:10.1111/jdv.18296.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2021;84(2):398–407. doi:10.1016/j.jaad.2020.09.047.
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–545. doi:10.4161/mabs.3.6.17815.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi:10.1056/NEJMoa1900750.
   PubMed Web of Science ®Google Scholar
• Wang CQF, Akalu YT, Suarez-Farinas M, et al. IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol. 2013;133(12):2741–2752. doi:10.1038/jid.2013.237.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. doi:10.1016/j.jaci.2017.07.004.
   PubMed Web of Science ®Google Scholar
• Girolomoni GSR, Puig L, Bachelez H, et al. The role of IL-23 and the IL-23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616–1626. doi:10.1111/jdv.14433.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580–592. doi:10.1056/NEJMoa062382.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39(3):242–252. doi:10.1111/j.1346-8138.2011.01347.x.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674. doi:10.1016/S0140-6736(08)60725-4.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684. doi:10.1016/S0140-6736(08)60726-6.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in taiwanese and korean patients (PEARL). J Dermatol Sci. 2011;63(3):154–163. doi:10.1016/j.jdermsci.2011.05.005.
   PubMed Web of Science ®Google Scholar
• Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166–174.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28(4):438–453. doi:10.1111/jdv.12118.
   PubMed Web of Science ®Google Scholar
• Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493–503. doi:10.1080/17512433.2020.1767590.
   PubMed Web of Science ®Google Scholar
• Bai F, Li GG, Liu Q, et al. Short-Term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network Meta-Analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161–2546125. doi:10.1155/2019/2546161.
   PubMed Web of Science ®Google Scholar
• Jun-Ren ZHU, Run-Lin GAO, Shui-Ping ZHAO, et al. Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1–29.
   PubMedGoogle Scholar
• Ng CY, Huang Y-H, Tzeng I-S, et al. Changes in metabolic parameters in psoriasis patients treated with interleukin-12/23 blockade (ustekinumab). Dermatol Sin. 2020;38(3):166–171. doi:10.4103/ds.ds_27_20.
   Web of Science ®Google Scholar
• Escolà-Gil JC, Julve J, Griffin BA, et al. HDL and lifestyle interventions. High Density Lipoproteins: from Biological Understanding to Clinical Exploitation. 2015;224:569–592. doi:10.1007/978-3-319-09665-0_18.
   Google Scholar
• Nikkilä EA, Taskinen M-R, Kekki M. Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man. Atherosclerosis. 1978;29(4):497–501. doi:10.1016/0021-9150(78)90178-8.
   PubMed Web of Science ®Google Scholar
• Peter Wolf M, Wolfgang Weger M, Thomas O, et al. Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function.
   Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis. J Clin Med. 2023;12(5):1934. doi:10.3390/jcm12051934.
   PubMed Web of Science ®Google Scholar
• Roig CA, Ferrer CS, García JLR, et al. Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease. Gastroenterología y Hepatología (English Edition). 2023;46(2):109–115. doi:10.1016/j.gastre.2022.05.003.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi:10.1016/j.jaad.2015.05.013.
   PubMed Web of Science ®Google Scholar
• Papp KA, Lebwohl MG, Puig L, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135–1145. doi:10.1111/bjd.20595.
   PubMed Web of Science ®Google Scholar
• Gonulal M, Balci DD, Ozturk A, et al. Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience. J Dermatolog Treat. 2023;34(1):2241941.
   PubMed Web of Science ®Google Scholar
• Van Voorhees AS, Mason MA, Harrold LR, et al. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US corrona psoriasis registry. J Dermatolog Treat. 2021;32(3):302–309. doi:10.1080/09546634.2019.1656797.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020;20(1):95–104. doi:10.1080/14712598.2020.1684472.
   PubMed Web of Science ®Google Scholar
• Colombo D, Bianchi L, Fabbrocini G, et al. The CANOVA study real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: a gender perspective. Womens Health Rep (New Rochelle). 2022;3(1):450–457. doi:10.1089/whr.2021.0124.
   PubMedGoogle Scholar
• Ya J, Hu JZ, Nowacki AS, et al. Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-α inhibitor-induced psoriasis: a case-control study. J Am Acad Dermatol. 2020;83(6):1599–1605. doi:10.1016/j.jaad.2020.06.081.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Griffiths CEM, Williams HC, et al. Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. Br J Dermatol. 2020;183(1):128–138. doi:10.1111/bjd.18622.
   PubMed Web of Science ®Google Scholar
• Solmaz D, Bakirci S, Kimyon G, et al. Impact of having family history of psoriasis or psoriatic arthritis on psoriatic disease. Arthritis Care Res (Hoboken). 2020;72(1):63–68. doi:10.1002/acr.23836.
   PubMed Web of Science ®Google Scholar
• Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf). 2006;64(4):355–365. doi:10.1111/j.1365-2265.2006.02474.x.
   PubMed Web of Science ®Google Scholar
• Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin. 2004;20(3):295–304. doi:10.1185/030079903125003008.
   PubMed Web of Science ®Google Scholar
• Hamminga EA, van der Lely AJ, Neumann HA, et al. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4):768–773. doi:10.1016/j.mehy.2005.11.050.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105(1):31–44. doi:10.1016/j.ad.2012.08.003.
   PubMedGoogle Scholar
• Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127–135. doi:10.1056/NEJMoa1001689.
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8–15. doi:10.1161/01.cir.79.1.8.
   PubMed Web of Science ®Google Scholar